Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mentice ABFRA:MN2 -4.15%75 EV-to-EBITDA is 12.59 as of Aug. 07, 2026, which is 47% below its 10-year median of 23.69. GuruFocus rates FRA:MN2 with a GF Score™ of 75/100 and a GF Value™ of €1.91 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 512 Medical Devices & Instruments companies, Mentice AB ranks better than 58.01% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Mentice AB's enterprise value is €33.13 Mil.
Mentice AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €2.63 Mil. Therefore, Mentice AB's EV-to-EBITDA for today is 12.59.
The historical rank and industry rank for Mentice AB's EV-to-EBITDA or its related term are showing as below:
FRA:MN2'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2267.95 Med: 23.69 Max: 19397.6
Current: 12.57
During the past 9 years, the highest EV-to-EBITDA of Mentice AB was 19397.60. The lowest was -2267.95. And the median was 23.69.
FRA:MN2's EV-to-EBITDA is ranked better than 58.01% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.645
vs FRA:MN2: 12.57
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Mentice AB's share price for today is €1.27.
Mentice AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.017.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Mentice AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Mentice AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mentice AB EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mentice AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Mentice AB's EV-to-EBITDA falls into.
Mentice AB's current Enterprise Value is €33.13 Mil.
Mentice AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mentice AB (FRA:MN2) has a EV-to-EBITDA of 12.59 as of Aug. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Mentice AB. This is 47% below median its historical median of 23.69. According to the industry distribution chart, Mentice AB ranks #215 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 42%.
Is Mentice AB's EV-to-EBITDA too high?
Mentice AB's current EV-to-EBITDA of 12.59 is 47% below median its 10-year median of 23.69. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.65. Mentice AB's value of 12.59 is 14% below this industry median. Based on the distribution chart, Mentice AB ranks #215 out of 512 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Mentice AB has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mentice AB's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mentice AB ranks #215 out of 512 companies for EV-to-EBITDA. This puts Mentice AB in the upper half of its industry. The industry median EV-to-EBITDA is 14.65. Mentice AB's value of 12.59 is 14% below this benchmark. While the company's 10-year median is 23.69 vs. the industry median of 14.65, Mentice AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.65, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mentice AB's current EV-to-EBITDA of 12.59 is 14% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Mentice AB. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mentice AB's current EV-to-EBITDA is 12.59, which is 47% below median its own 10-year median of 23.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mentice AB stock overvalued right now?
Based on GuruFocus' analysis, Mentice AB (FRA:MN2) is currently considered Significantly Undervalued. The stock's GF Value™ is €1.91, compared to a current price of €1.27 — trading 33.5% below its estimated fair value. The current EV-to-EBITDA is 12.59, which is 47% below median its 10-year median of 23.69 and 14% below the Medical Devices & Instruments industry median of 14.65. Mentice AB's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Mentice AB (FRA:MN2), the current EV-to-EBITDA is 12.59 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mentice AB (FRA:MN2) Overvalued in 2026?
Based on GuruFocus' analysis, Mentice AB stock appears to be undervalued.
The current stock price of €1.27 is trading 33.5% below its estimated GF Value™ of €1.91.
GuruFocus considers Mentice AB to be Significantly Undervalued.
Key valuation signals for FRA:MN2:
EV-to-EBITDA: 12.59 (47% below median its 10-year median of 23.69)
GF Value™: €1.91 vs. price of €1.27 (33.5% below fair value)
Industry Position: 14% below the Medical Devices & Instruments median (#215 of 512)
No single metric tells the full story. See the FRA:MN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mentice AB is a provider of software and hardware simulation solutions for image guided interventional therapies, offering proficiency based simulation solutions that help healthcare professionals acquire, retain, and enhance procedural skills, improving productivity and outcomes. Its solutions are scientifically validated and developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are covered. Mentice operates in two segments: Medical Device Industry (MDI), providing end-to-end solutions supporting development and launch of interventional therapies, and Healthcare Systems (HCS). Product areas include Mentice VIST, Physical Sim, Mentice Live, and Ankyras. It operates in EMEA, APAC, and the Americas.
75GF Score
Get the complete analysis for FRA:MN2
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MN2 has been successfully added to your 
